Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of ...
Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, toda...
NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"...
Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated wi...
On Thursday, 94 companies set new 52-week lows.
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thora...
Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for ...
Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated wit...
Clinical study found that cudetaxestat, a non-competitive inhibitor of autotaxin, was well tolerated and showed no reports of...
